Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from C4 Therapeutics ( (CCCC) ) is now available.
On October 16, 2025, C4 Therapeutics announced the presentation of data from its Phase 1 clinical trial of cemsidomide combined with dexamethasone for relapsed/refractory multiple myeloma, highlighting its potential efficacy and safety profile. Additionally, the company terminated a sales agreement prospectus with TD Securities, impacting its stock sale strategy, while maintaining the agreement’s validity for future use, having previously raised approximately $9.6 million through stock sales.
The most recent analyst rating on (CCCC) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.
Spark’s Take on CCCC Stock
According to Spark, TipRanks’ AI Analyst, CCCC is a Neutral.
C4 Therapeutics’ stock score is primarily impacted by its financial struggles, with ongoing losses and negative cash flows. Technical indicators suggest weak market momentum, and the valuation is unattractive due to a negative P/E ratio. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on CCCC stock, click here.
More about C4 Therapeutics
C4 Therapeutics, Inc. operates in the biotechnology industry, focusing on developing targeted protein degradation therapies. The company is known for its TORPEDO platform and its portfolio includes products like cemsidomide, aimed at treating conditions such as multiple myeloma and non-Hodgkin’s lymphoma.
Average Trading Volume: 1,804,697
Technical Sentiment Signal: Sell
Current Market Cap: $158M
See more insights into CCCC stock on TipRanks’ Stock Analysis page.